China’s Fifth New Corona Vaccine Enters Phase III Clinical Trial To Be Conducted In Uzbekistan

Original title: China’s fifth new crown vaccine enters phase III clinical trials, and Uzbekistan will include 5,000 volunteers

Summary

[La quinta nueva vacuna de la corona de China entra en ensayos clínicos de Fase III y se llevará a cabo en Uzbekistán]According to news from the English version of Xinhuanet on November 14, the Uzbek government recently told the media that it was developed by Anhui Zhifeilongkoma Biological Pharmaceutical Co. The new corona vaccine will carry out phase III clinical trials in Uzbekistan. This is the fifth vaccine candidate from China to enter phase III clinical trials. (Paper)

China’s fifth new corona vaccine has entered phase III clinical trials, to be conducted in Uzbekistan.

according toXinhuanetThe English version of the November 14 news, the Uzbek government recently told the media that Anhui Zhifeilongkoma Biopharmaceutical Co., Ltd.the company(Hereinafter “Zhifeilongkoma”) The new corona vaccine developed in Uzbekistan will carry out phase III clinical trials. This is the fifth vaccine candidate from China to enter phase III clinical trials.

　　XinhuanetScreenshots of the English version The news also indicated that the vaccine has been delivered to Uzbekistan and that several Chinese experts have also been installed who will be responsible for monitoring the volunteers and training the Uzbek doctors.

According to the Xinjiang Branch of the China News ServicepublicNo. “New Observation on the Silk Road” October 30, prevention and control of the epidemic in UzbekistanjobsAn expert at headquarters said: “If the volunteers have any complications or adverse reactions, they will be treated free of charge. In addition, the volunteers for the new vaccination crown can also receive the corresponding subsidies.” Previously, Uzbekistan Minister of Innovation and Development Yi Brahim Abdullahmonov into acceptUzbekistan television channel 24 said in an interview that the safety of the new corona vaccine produced in China is much higher than that of other similar vaccines.

According to Reuters Eaststandard timeOn November 11, it was reported that Uzbekistan had stated that it was also working with the Sinopharm Group and the Russian vaccine manufacturer “Satellite V” on possible trials.negotiation. More than 69,000 people have been diagnosed with the new crown in Uzbekistan, with 589 deaths and around 200 new cases in a single day. Uzbekistan imposed a national blockade twice, but there are no plans for another blockade. Uzbekistan’s President Mirziyoyev has instructed officials to learn frompopularLives and works under the state.

The vaccine, which will enter phase III clinical trials, was jointly developed by the Institute of Microbiology, the Chinese Academy of Sciences and Zhifeilongkoma.

According to the earlier announcement by the Institute of Microbiology of the Chinese Academy of Sciences, on June 19 the vaccine was officially approved by the State Drug Administration.administrationApproval of clinical trials for local drugs and initiation of clinical trials. Recruitment of healthy adults ages 18 to 59 in Beijing, Chongqing and Hunan Province began on June 23. Phase I clinical trials began at Chongqing Medical University Second Affiliated Hospital and Beijing Chaoyang Hospital. The Clinic II launched on July 10 Periodic Test. On October 22, the phase I / II clinical trial of the vaccine was not blindedmeetingCelebrated, the revealing result was in line with expectations, the new corona virusReorganizationThe subunit vaccine has good safety and immunogenicity in the population that complies with the clinical trial protocol, and it can be continued with the next clinical trial.

Genetically Engineered Recombinant Subunit Vaccines, Also Known As Recombinant Protein Vaccines About This And Zhifei LongkomaCooperative research and developmentAccording to the technical characteristics of the vaccine, the Institute of Microbiology of the Chinese Academy of Sciences once introduced that recombinant protein vaccines express and purify pathogenic antigen proteins in genetically engineered cells and then prepare them into vaccines. Gao futeamThe antigen in this new coronavirus vaccine developed by Yan Jinghua’s team is a protein S receptor domain (RBD) dimer antigen based on a structural design. It has a unique structure and does not carry any exogenous formlabel, With autonomyKnowledgeproperty. The hACE2 transgenic mouse challenge experiment demonstrated that the vaccine has an obvious protective effect. The results of the challenge and protection tests of the Rhesus monkey show that the immunity of the vaccine can induce high levels of neutralizing antibodies, significantly reduce the viral load of lung tissue, reduce the lung damage caused by virus infection and have protective effects obvious.The vaccine is carried out through a cell line designedindustryChemical production, high productivity,costLow, with strong accessibility.

This vaccine is a key research and development program of a special national emergency project “public safetyriskKey special project of “Technical Equipment for Prevention, Control and Emergencies” (Project Number: 2020YFC0842300), the technical route is the “Recombinant subunit vaccine” in the “5 routes” of the new corona vaccine deployed by the Ministry of Science and Technology.

This recombinant subunit vaccine is China’s fifth vaccine to enter Phase III clinical trials. The four above vaccines entered Phase III clinical trials using two technical routes, inactivated vaccines and adenovirus vector vaccines. The four vaccines are two inactivated vaccines developed by Sinopharm Group, an inactivated vaccine developed by Kexing Zhongwei, and an adenovirus vector vaccine developed by Academician Chen Wei’s team.

On October 20, the State Council for Prevention and Joint ControlmechanismSpecialty in Vaccine Research and Development of the Scientific Research GroupteamZheng Zhongwei, director of the National Health Commission’s Medical Science and Technology Development Center, once said at the press conference that the first four vaccines that entered the phase III clinical trial stage are progressing generally smoothly. . So far, a total of approximately 60,000 subjects have been vaccinated. , No serious adverse reactionsreportIt initially showed good security.

(Source: The Paper)

(Editor in charge: DF142)